{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:01:12Z","timestamp":1762297272394,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijrobp.2025.01.030","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:06:33Z","timestamp":1738670793000},"page":"399-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial"],"prefix":"10.1016","volume":"122","author":[{"given":"Martin","family":"Lang\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Renouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaury","family":"Paumier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Bera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Catton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.030_bib0001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0002","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0003","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2022.06.014","article-title":"Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate Fractionated Irradiation Trial \u2013 PROFIT","volume":"173","author":"Zhou","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0006","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0008","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/11591500-000000000-00000","article-title":"Pharmacotherapeutic management of locally advanced prostate cancer: current status","volume":"71","author":"Martin","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0009","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0012","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.canrad.2014.07.153","article-title":"Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?","volume":"18","author":"Cr\u00e9hange","year":"2014","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0013","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: Phase 1 results from the GETUG-AFU 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0014","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: A pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0016","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ijrobp.2023.02.039","article-title":"Patterns of failure in men with radiorecurrent prostate cancer: A post hoc analysis of 3 prospective gallium 68 prostate-specific membrane antigen positron emission tomography\/computed tomography imaging trials","volume":"116","author":"Smith","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0017","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer","volume":"194","author":"Zumsteg","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0018","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0019","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 2","key":"10.1016\/j.ijrobp.2025.01.030_bib0020","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2023.06.210","article-title":"Long-term outcomes of NRG\/RTOG 0126, a randomized trial of high dose (79.2 Gy) vs. standard dose (70.2 Gy) radiation therapy (RT) for men with localized prostate cancer","volume":"117","author":"Michalski","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0022","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0023","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0024","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: An individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0027","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00259-019-04568-1","article-title":"Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer","volume":"47","author":"Ferraro","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0028","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0029","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: A systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.ijrobp.2025.01.030_bib0030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:50:49Z","timestamp":1762296649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0360301625000896"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.030","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}